5 key trial insights from ESMO 2025

Urology Times® was on-site at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany conducting interviews with experts on key data presented at the meeting. In the following video, we feature 5 interviews with presenting authors of top study readouts.

Specifically, we showcase:

• Christof Vulsteke, MD, PhD: “Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study”
• Stephen J. Freedland, MD: “EMBARK: Overall survival with enzalutamide in biochemically recurrent prostate cancer.”
• Srikala Sridhar, MD, MSc, FRCPC: “A phase II study of avelumab in locally advanced or metastatic penile cancer patients unfit for platinum-based chemotherapy or progressed on or after platinum-based chemotherapy (ALPACA)”
• Scott T. Tagawa, MD, MS, FACP, FASCO: “Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)”
• Katy Beckermann, MD, PhD: “Phase Ib/II trial of ipilimumab, nivolumab, and ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma (RCC), a kidney cancer research consortium study”

These 5 videos represent a snapshot of all of the data that were covered at this year’s meeting. You can view our full ESMO 2025 coverage here. To stay even more informed on the latest from Urology Times, subscribe to our newsletters!